Vendor Intelligence Report: Yidan Biotech

Published 2 Jul 2026. 16-page investigative report on who is behind Yidan Biotech: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 8 Finnrick lab tests, Yidan Biotech records 6 pass / 2 fail — an overall pass rate of 75%. The dataset is narrow, covering only Retatrutide and Tirzepatide. Both GLP-1s show majority-pass performance, but neither has avoided failure, and ratings contract under stricter Finnrick grading. If a buyer is locked into Yidan, the signal is cautious-use rather than clean-repeat.

The vendor is more traceable than many gray-market peptide storefronts. The report ties yidanbio.com to Shanghai Yidan Biotechnology Co., Ltd., a company registered in 2017, with Wang Peng named as legal representative. That positive identity signal still does not resolve beneficial ownership, manufacturing custody, freight providers or batch-level quality controls.

The storefront’s weak point is seller-specific evidence. Product pages use polished scientific narration, but the Retatrutide capture lacks batch-specific COAs, purity specifications, fill/quantity tolerances and lot tracking. A refund-policy page also says “Bestway” offers replacement, documenting off-brand template reuse or copying while leaving any Bestway relationship unresolved.

Public reputation is thin rather than openly toxic: searches found no substantive English-language forum trail, direct FDA warning letter, reverse-IP sister-brand cluster or public X/coupon network. The harder-to-verify risk sits off-platform: field notes observed Sunny-branded Instagram/TikTok sales paths using a different +852 WhatsApp, while CBP’s 2026 China-origin GLP-1 seizure record makes Yidan’s undocumented shipping lane materially relevant without proving Yidan was seized.

Inside the full report:

  • Full per-product lab appendix, methodology-divergence charts and trajectory plots for Retatrutide and Tirzepatide
  • Chinese corporate-identity record and look-alike disambiguation, including registration code, legal representative, Shanghai address, Hangzhou Yidan and Shanghai Yidian
  • Storefront QA review of the Retatrutide page’s missing COA, purity, fill and lot controls
  • Refund-policy artifact documenting the off-brand Bestway wording and open linkage analysis
  • DNS/contact-channel review covering +852 numbers, reverse-IP results and Sunny Instagram/TikTok leads
  • CBP Cincinnati 2026 GLP-1 import-exposure analysis, with direct-Yidan caveats

Risk assessment

  • Product-specific quality inconsistency: Retatrutide and Tirzepatide — high: Finnrick record is 8 tests total, 6 pass / 2 fail; Retatrutide is 78.77% (3/4) and Tirzepatide is 78.51% (3/4), leaving both products below a clean-record profile.
  • Customs-seizure exposure for China-origin Retatrutide/Tirzepatide — high: CBP reported 5,000+ China-origin shipments of unapproved peptides including Retatrutide and Tirzepatide; no supplied evidence ties Yidan shipments to the seizure, but the products and origin match the enforcement focus.
  • Batch-verification and documentation deficit — medium: Observed product presentation lacks batch-specific COAs, purity specifications, fill tolerance and lot tracking; this is material because the tested products already show failures.
  • Affiliate and alternate-sales-channel accountability risk — medium: Instagram/TikTok promotion was observed using alternate WhatsApp +852 9757 3597 while X/web/coupon sweeps found no public referral network; authority, disclosure and accountability remain unverified.
  • Brand-accountability confusion from template reuse and look-alike names — medium: The refund policy references the word Bestway and similarly named Chinese biotech/pharma entities are unrelated, leaving buyers dependent on exact-domain and company-code verification.